|
LICENSE AGREEMENTS (Details Textual) (USD $)
|
9 Months Ended | 101 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Apr. 08, 2011
|
Dec. 31, 2009
Collaboration Agreement [Member]
|
Sep. 30, 2003
University Of Michigan Agreement [Member]
|
Dec. 31, 2011
University Of Michigan Agreement [Member]
|
Dec. 31, 2010
University Of Michigan Agreement [Member]
|
Dec. 31, 2003
University Of Michigan Agreement [Member]
|
Sep. 30, 2003
University Of Michigan Agreement [Member]
New Drug Application [Member]
|
Sep. 30, 2003
University Of Michigan Agreement [Member]
Maximum [Member]
|
Sep. 30, 2003
University Of Michigan Agreement [Member]
Minimum [Member]
|
Sep. 30, 2003
University Of Michigan Agreement [Member]
Patents [Member]
|
Sep. 30, 2003
University Of Michigan Agreement [Member]
Rights [Member]
|
Dec. 31, 2006
Wisconsin Alumni Research Foundation Agreement [Member]
|
Dec. 31, 2006
Wisconsin Alumni Research Foundation Agreement [Member]
Maximum [Member]
|
Dec. 31, 2006
Wisconsin Alumni Research Foundation Agreement [Member]
Minimum [Member]
|
Dec. 31, 2006
2007 Novelos Licesnce agreement [Member]
|
Dec. 31, 2006
2007 Novelos Licesnce agreement [Member]
Lees Pharmaceutical (Hk) Ltd [Member]
Maximum [Member]
|
Dec. 31, 2006
2007 Novelos Licesnce agreement [Member]
Lees Pharmaceutical (Hk) Ltd [Member]
Minimum [Member]
|
|
| Agreement Expiration Period | 15 years | 2016 | ||||||||||||||||
| Payment Of Licence Fee | $ 10,000 | $ 8,800 | ||||||||||||||||
| Payment Of Milestone Expenses | 400,000 | 50,000 | ||||||||||||||||
| Milestone Payment Method Description | such milestone fees may be deferred and paid within 12 months of the first commercial sale of such products | |||||||||||||||||
| Future Milestone Payments | 200,000 | 100,000 | 1,700,000 | |||||||||||||||
| Percentage Of Royalty Revenue | 3.00% | 0.30% | 15.00% | 12.00% | 25.00% | 12.00% | ||||||||||||
| Payment Of Sublicence Fee Description | if the sublicense fee payable to the Company is between 4% and 5% of net sales, then the royalties payable to U. Mich. Shall be equal to 50% of the sublicense fee. | |||||||||||||||||
| Percentage Of Revenue Received In Kind | 10.00% | |||||||||||||||||
| Termination Of Agreement Description | The Company may terminate the Collaboration Agreement upon breach or default by Mundipharma. Mundipharma may terminate the Collaboration Agreement upon breach or default, filing of voluntary or involuntary bankruptcy by Novelos, the termination of certain agreements with companies associated with the originators of the licensed technology, or 30-day notice for no reason. | U. Mich. may terminate the agreement if the Company ceases operations, if the Company fails to make any required payment under the agreement, or if the Company otherwise materially breaches the agreement, subject to the applicable notice and cure periods. To date, the Company has made all payments as they have become due, there have been no defaults under the U. Mich. Agreement, nor has the Company been notified of a default by U. Mich. The Company may terminate the agreement with six months'' notice to U. Mich. and the return of licensed product and related data. | ||||||||||||||||
| Reimbursement Of Patent Maintenance Fees | 600 | 300 | ||||||||||||||||
| Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend | 54,000 | |||||||||||||||||
| Issuance of common stock (in shares) | 6,846,537 | 12,559,218 | 203,483 | |||||||||||||||
| Issuance of common stock | $ 4,870,978 | $ 80,412 | ||||||||||||||||
| Percentage Of Reduction In Market Share | 20.00% | |||||||||||||||||